IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
Open Access
- 20 July 2012
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 41 (4), 1325-1336
- https://doi.org/10.3892/ijo.2012.1564
Abstract
Reliable prognostic biomarkers of grade II gliomas remain unclear. This study aimed to examine the role of mutations of isocitrate dehydrogenase (IDH1/2), 1p/19q co-deletion, and clinicopathological factors in patients with grade II glioma who were primarily treated with radiotherapy or chemoradiotherapy after surgery. Seventy-two consecutive patients, including 49 cases of diffuse astrocytomas (DA), 4 oligodendrogliomas (OL) and 19 oligoastrocytomas (OA), who underwent treatment from 1991 to 2010 at a single institution were examined. The overall survival (OS) of the DA patients (8.3 years) was significantly shorter than that of the OL and OA patients (11.7 years). IDH1/2 mutations were found in 46.9% of the DA patients and 82.6% of the OL and OA patients. The progression-free survival (PFS) and OS of the patients with IDH1/2 mutations (8.4 and 16.3 years) were significantly longer than those of the patients without IDH1/2 mutations (3.3 and 4.5 years). Among the patients with IDH1/2 mutations, those who were initially treated with chemoradiotherapy including nimustine hydrochloride (ACNU), had significantly longer PFS than those treated with radiotherapy alone, whereas no significant difference in PFS was observed between the chemoradiotherapy and radiotherapy groups in the patients without IDH1/2 mutations. Oligodendroglial tumors, age <40 years, initial Karnofsky performance status (KPS) ≥80, and IDH1/2 mutations were favorable prognostic factors regarding PFS and OS. IDH1/2 mutation was a predictive factor of response to chemoradiotherapy in grade II gliomas. Patients with IDH1/2 mutations may benefit more from chemoraiotherapy than those without IDH1/2 mutations.Keywords
This publication has 31 references indexed in Scilit:
- Adult Supratentorial Low-Grade Glioma: Long-Term Experience at a Single InstitutionInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Preoperative prognostic classification system for hemispheric low-grade gliomas in adultsJournal of Neurosurgery, 2008
- Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG)Journal of Clinical Oncology, 2008
- Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric GliomasJournal of Clinical Oncology, 2008
- Outcome in adult low-grade gliomaNeurology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trialThe Lancet, 2005
- Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade GliomaJournal of Clinical Oncology, 2002
- Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysisInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtypeOncogene, 1999